Abstract:Iron is required for most forms of organisms, and it is the most essential element for the functions of many iron-containing proteins involved in oxygen transport, cellular respiration, DNA replication, and so on. Disorders of iron metabolism are associated with diverse diseases, including anemias (e.g., iron-deficiency anemia and anemia of chronic diseases) and iron overload diseases, such as hereditary hemochromatosis and beta-thalassemia. Hepcidin (encoded by Hamp gene) is a peptide hormone synthesized by hepatocytes, and it plays an important role in regulating the systematic iron homeostasis. As the systemic iron regulator, hepcidin, not only controls dietary iron absorption and iron egress out of iron storage cells, but also induces iron redistribution in various organs. Deregulated hepcidin is often seen in a variety of iron-related diseases including anemias and iron overload disorders. In the case of iron overload disorders (e.g., hereditary hemochromatosis and beta-thalassemia), hepatic hepcidin concentration is significantly reduced.Since hepcidin deregulation is responsible for iron disorder-associated diseases, the purpose of this review is to summarize the recent findings on therapeutics targeting hepcidin.Continuous efforts have been made to search for hepcidin mimics and chemical compounds that could be used to increase hepcidin level. Here, a literature search was conducted in PubMed, and research papers relevant to hepcidin regulation or hepcidin-centered therapeutic work were reviewed. On the basis of literature search, we recapitulated recent findings on therapeutic studies targeting hepcidin, including agonists and antagonists to modulate hepcidin expression or its downstream signaling. We also discussed the molecular mechanisms by which hepcidin level and iron metabolism are modulated.Elevating hepcidin concentration is an optimal strategy to ameliorate iron overload diseases, and also to relieve beta-thalassemia phenotypes by improving ineffective erythropoiesis. Relative to the current conventional therapies, such as phlebotomy and blood transfusion, therapeutics targeting hepcidin would open a new avenue for treatment of iron-related diseases.

Physiological and Pathophysiological Mechanisms of Hepcidin Regulation: Clinical Implications for Iron Disorders

Hepcidin: A Promising Therapeutic Target for Iron Disorders: A Systematic Review.

Iron metabolism and iron disorders revisited in the hepcidin era

Hepcidin Signaling in Health and Disease: Ironing Out the Details

Hepcidin-Ferroportin Interaction Controls Systemic Iron Homeostasis

Hepcidin: from discovery to differential diagnosis

Hepcidin and Iron in Health and Disease

Advance in Hepcidin

Deregulation of proteins involved in iron metabolism in hepcidin-deficient mice

An overview of molecular basis of iron metabolism regulation and the associated pathologies

Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation

The regulatory roles of hepcidin on body iron homeostasis

Reciprocal Regulation Between Hepcidin and Erythropoiesis and Its Therapeutic Application in Erythroid Disorders

Effect of hepcidin antagonists on anemia during inflammatory disorders

Relationship Between Iron Overload Caused by Abnormal Hepcidin Expression and Liver Disease: A Review

Mechanisms controlling cellular and systemic iron homeostasis

Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization

Systemic iron homeostasis and erythropoiesis

New insights into the links between hypoxia and iron homeostasis

Roles of the hepcidin-ferroportin axis and iron in cancer.

The Progress of the Research on the Hepcidin and Its Mechanism